Do patents prevent access to drugs for HIV in developing countries?

Journal of the American Medical Association

Volumn 287, Issue 7, 2002, Pages 840-843

  Boelaert, Marleen ^a   Lynen, Lut ^a   van Damme, Wim ^a   Colebunders, Robert ^a   Goemaere, Eric ^a   Kaninda, Anne Valerie ^a   Ciaffi, Laura ^a   Mulemba, Maryline ^a   ’T Hoen, Ellen ^a   Pécoul, Bernard ^a   Selgelid, Michael J ^b   Schuklenk, Udo ^b   Attaran, Amir ^c   Gillespie White, Lee ^c  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c HARVARD UNIVERSITY   (United States)

Author keywords

Africa; Antihiv agents; Antiretroviral therapy, highly active; Costs and cost analysis; Developing countries; Drug costs; Drug industry; Highly active antiretroviral therapy; HIV infections; Patents

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; GENERIC DRUG; ANTIRETROVIRUS AGENT; CIPROFLOXACIN; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

AFRICA; DEVELOPING COUNTRY; DRUG INDUSTRY; ECONOMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; NOTE; PATENT; ACQUIRED IMMUNE DEFICIENCY SYNDROME; COMBINATION CHEMOTHERAPY; DRUG COST; DRUG LEGISLATION; HEALTH CARE ACCESS; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LICENSING; PRIORITY JOURNAL; UNITED STATES;

AFRICA; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DEVELOPING COUNTRIES; DRUG INDUSTRY; DRUGS, GENERIC; PATENTS;

EID: 0037138790     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.7.840     Document Type: Letter

References (0)